This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thompson, I. M. Articles by Coltman, C. A. Search for Related Content PubMed PubMed Citation Articles by Thompson, I. M. Articles by Coltman, C. A., Jr Related Articles Related Editorial

Prediction of Prostate Cancer for Patients Receiving Finasteride: Results From the Prostate Cancer Prevention Trial

Ian M. Thompson, Donna Pauler Ankerst, Chen Chi, Phyllis J. Goodman, Catherine M. Tangen, Scott M. Lippman, M. Scott Lucia, Howard L. Parnes, Charles A. Coltman, Jr

From the Department of Urology, University of Texas Health Sciences Center at San Antonio; Southwest Oncology Group, San Antonio; Department of Clinical Cancer Prevention, The University of Texas M.D. Anderson Cancer Center, Houston, TX; The Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Pathology, University of Colorado Health Sciences Center, Denver, CO; and the Department of Cancer Prevention, National Cancer Institute, Washington, DC

Address reprint requests to Ian M. Thompson, MD, Department of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229; e-mail: thompsoni{at}uthscsa.edu

Purpose: Using data from men in the finasteride group of the Prostate Cancer Prevention Trial (PCPT), we evaluated the impact of prostate-specific antigen (PSA) and other risk factors on the risk of prostate cancer.

Methods: Four thousand four hundred forty men in the finasteride group of the PCPT underwent prostate biopsy, had at least one PSA and a digital rectal exam (DRE) during the year before biopsy, had at least two PSA values from the 3 years before biopsy, and were on finasteride at the time of PSA evaluation. Logistic regression was conducted using the variables age, race, family history of prostate cancer, PSA, PSA velocity, and DRE adjusting for history of prior prostate biopsy.

Results: Six hundred forty-nine (14.6%) of 4,440 men were diagnosed with prostate cancer; 250 had Gleason 7 or higher cancer. Factors associated with an increased risk of prostate cancer included high PSA value and a rising PSA (24.9% risk for PSA value of 1.0 ng/mL and 24.8% risk for a rising PSA), family history of prostate cancer, abnormal DRE result, African American race, and older age. Factors associated with an increased risk of Gleason 7 or higher grade prostate cancer included PSA, abnormal DRE, and older age. A prior negative biopsy was associated with decreased risk of prostate cancer and high-grade prostate cancer.

Conclusion: Risk factors for prostate cancer on biopsy for men receiving finasteride include PSA, DRE, age, race, family history, and history of a prior negative biopsy. With the exception of the approximate reduction of PSA by half with finasteride, the impact of these risk factors is similar to men who do not receive finasteride.

Supported in part by PHS Cooperative Agreement Grants No. CA37429, CA35178, CA45808, and 5UO1CA86402-04 from the National Cancer Institute, Department of Health and Human Services.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Related Editorial

• Finasteride for Chemoprevention of Prostate Cancer: Why Has It Not Been Embraced?
  Ralph W. de Vere White
  JCO 2007 25: 2999-3000 [Full Text]

This article has been cited by other articles:

				R. W. de Vere White Finasteride for Chemoprevention of Prostate Cancer: Why Has It Not Been Embraced? J. Clin. Oncol., July 20, 2007; 25(21): 2999 - 3000. [Full Text] [PDF]